Helen Colley

Dr. Helen Colley


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2022 in Oral Diseases
Verified
Journal Article
Closed access
PDF file
AEAsma El‐Howati
Asma El‐Howati
MTMartin H Thornhill
Martin H Thornhill
HCHelen Colley
Helen Colley
CMCriag Murdoch
Criag Murdoch

11 October 2011 in British Journal of Cancer
Verified
Journal Article
Open access
HCHelen Colley
Helen Colley
VHVanessa Hearnden
Vanessa Hearnden
AJA V Jones
A V Jones
PWP H Weinreb
P H Weinreb
SVS M Violette
S M Violette
CMCriag Murdoch
Criag Murdoch
Background: Methods: Results: Conclusion:

16 July 2019 in Journal of Oral Pathology & Medicine
Verified
Journal Article
Closed access
PDF file
CLChristopher J. Legge
Christopher J. Legge
HCHelen Colley
Helen Colley
MLMichelle A. Lawson
Michelle A. Lawson
ARAndrea E. Rawlings
Andrea E. Rawlings

10 August 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
CLCristina Quílez Lopez
Cristina Quílez Lopez
LBLuís Bebiano
Luís Bebiano
EJEleri Jones
Eleri Jones
Uroš MaverUroš Maver
Uroš Maver
LMLuca Meesters
Luca Meesters
Diego VelascoDiego Velasco
Diego Velasco
Skin in vitro models offer much promise for research, testing drugs, cosmetics, and medical devices, reducing animal testing and extensive clinical trials. There are several in vitro approaches to mimicking human skin behavior, ranging from simple cell monolayer to complex organotypic and bioengineered 3-dimensional models. Some have been approved for preclinical studies in cosmetics, pharmaceuticals, and chemicals. However, development of physiologically reliable in vitro human skin models remains in its infancy. This review reports on advances in in vitro complex skin models to study skin homeostasis, aging, and skin disease.

2 June 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JEJake Edmans
Jake Edmans
KCKatharina H. Clitherow
Katharina H. Clitherow
CMCriag Murdoch
Criag Murdoch
PHPaul Hatton
Paul Hatton
SSSebastian Guy Spain
Sebastian Guy Spain
HCHelen Colley
Helen Colley
Oral disease greatly affects quality of life, as the mouth is required for a wide range of activities including speech, food and liquid consumption. Treatment of oral disease is greatly limited by the dose forms that are currently available, which suffer from short contact times, poor site specificity, and sensitivity to mechanical stimulation. Mucoadhesive devices prepared using electrospinning offer the potential to address these challenges by allowing unidirectional site-specific drug delivery through intimate contact with the mucosa and with high surface areas to facilitate drug release. This review will discuss the range of electrospun mucoadhesive devices that have recently been reported to address oral inflammatory diseases, pain relief, and infections, as well as new treatments that are likely to be enabled by this technology in the future.

1 July 2020 in Materials Science and Engineering: C
Verified
Journal Article
Open access
JEJake G. Edmans
Jake G. Edmans
CMCraig Murdoch
Craig Murdoch
MSMartin E. Santocildes-Romero
Martin E. Santocildes-Romero
PHPaul Hatton
Paul Hatton
HCHelen Colley
Helen Colley
SSSebastian G. Spain
Sebastian G. Spain
The delivery of biopharmaceuticals to the oral mucosa offers a range of potential applications including antimicrobial peptides to treat resistant infections, growth factors for tissue regeneration, or as an alternative to injections for systemic delivery. Existing formulations targeting this site are typically non-specific and provide little control over dose. To address this, an electrospun dual-layer mucoadhesive patch was investigated for protein delivery to the oral mucosa. Lysozyme was used as a model antimicrobial protein and incorporated into poly(vinylpyrrolidone)/Eudragit RS100 polymer nanofibers using electrospinning from an ethanol/water mixture. The resulting fibrous membranes released the protein at a clinically desirable rate, reaching 90 ± 13% cumulative release after 2 h. Dual fluorescent fibre labelling and confocal microscopy demonstrated the homogeneity of lysozyme and polymer distribution. High encapsulation efficiency and preservation of enzyme activity were achieved (93.4 ± 7.0% and 96.1 ± 3.3% respectively). The released lysozyme inhibited the growth of the oral bacterium Streptococcus ratti, providing further evidence of retention of biological activity and illustrating a potential application for treating and preventing oral infections. An additional protective poly(caprolactone) backing layer was introduced to promote unidirectional delivery, without loss of enzyme activity, and the resulting dual-layer patches displayed long residence times using an in vitro test, showing that the adhesive properties were maintained. This study demonstrates that the drug delivery system has great potential for the delivery of therapeutic proteins to the oral mucosa.